Treatment of cancers with immunostimulatory HIV TAT derivative polypeptides
Disclosed herein are methods of treating cancer by administering a modified Human Immunodeficiency Virus (HIV) trans-activator of transcription (Tat) polypeptide with increased immunostimulatory properties relative to the non-modified Tat polypeptide.
1. A pharmaceutical composition comprising a polypeptide with greater than 85% sequence identity to the amino acid of SEQ ID NO: 4, wherein the peptide is a modified amino acid sequence of Human Immunodeficiency Virus (HIV) trans-activator of transcription (Tat) protein.
2. A method of treating breast cancer comprising:
administering a therapeutically effective amount of the pharmaceutical composition of claim 1 to a subject in need thereof, wherein administration of the pharmaceutical composition causes cessation of growth of said cancer or regression of said cancer in said subject.
3. The method of claim 2 , wherein said pharmaceutical composition is administered in a plurality of doses.
4. The method of claim 2 , wherein said administering step comprises a repetitive administration cycle wherein each cycle comprises administering a plurality of doses of said pharmaceutical composition in a defined time period followed by a rest period and wherein said cycle is repeated a plurality of times.
5. The method of claim 2 , wherein said administering step comprises a repetitive administration cycle wherein each cycle comprises administering a plurality of doses of said pharmaceutical composition in a defined time period followed by an administration of one or a plurality of doses of a therapeutic agent in a defined time period and wherein said cycle is repeated a plurality of times.
6. The method of claim 5 , wherein the therapeutic agent is cyclophosphamide.
7. A method of reducing breast cancer tumor burden comprising: administering a therapeutically effective amount of the pharmaceutical composition of claim 1 to a subject in need thereof, wherein administration of the pharmaceutical composition causes regression of said cancer in said subject.
8. The method of claim 7 , wherein said pharmaceutical composition is administered in a plurality of doses.
9. The method of claim 7 , wherein said administering step comprises a repetitive administration cycle wherein each cycle comprises administering a plurality of doses of said pharmaceutical composition in a defined time period followed by a rest period and wherein said cycle is repeated a plurality of times.
10. The method of claim 7 , wherein said administering step comprises a repetitive administration cycle wherein each cycle comprises administering a plurality of doses of said pharmaceutical composition in a defined time period followed by an administration of one or a plurality of doses of a therapeutic agent in a defined time period and wherein said cycle is repeated a plurality of times.
11. The method of claim 10 , wherein the therapeutic agent is cyclophosphamide.
12. A polypeptide having greater than 85% sequence identity to the amino acid sequence of SEQ ID NO: 4.